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Abstract
The platelet-derived growth factor receptor (PDGFR) is
a receptor tyrosine kinase overexpressed in a subset
of solid tumors and therefore is the target of drugs
inhibiting this function such as imatinib mesylate
(Gleevec). Thus far, drug therapy has played a limited
role in the treatment of localized prostate cancer (PCa).
This study characterizes PDGFR-b expression in a
wide spectrum of PCa samples to provide empirical
data as part of a rational treatment strategy. A survey
of five published prostate expression array studies,
including 100 clinically localized PCa, did not identify
tumors with increased PDGFR-b expression level.
Protein expression of PDGFR-b, as determined by
immunohistochemistry, revealed 5% of clinically lo-
calized PCa and 16% of metastatic PCa cases to show
moderate or strong expression. To develop a strategy
to detect patients most likely to profit from Gleevec
treatment, we analyzed cDNA expression array data
from 10,000 transcripts for PDGFR-b expression and
divided tumors in groups based on PDGFR-b expres-
sion level. Performing a supervised analysis to identify
potential comarkers of PDGFR-b in PCa, we identified a
set of genes whose expression was associated with
PDGFR-b status including early growth response 1
(Egr1), an upstream effector of PDGF (4.2-fold upregu-
lation), A-methylacyl-CoA racemase, as well as v-Maf
and neuroblastoma suppressor of tumorigenicity
(both with a 2.2-fold downregulation). Taken together,
this study suggests that only a small subset of PCas
may be amenable to tyrosine kinase inhibitors specific
for PDGFR.
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Introduction
Prostate cancer (PCa) is the second leading cause of
male cancer–related death after lung cancer in the United
States [1]. Currently, there is no standard approach for the
treatment of clinically localized and locally advanced PCa.
Treatment options include radical prostatectomy, radiation
therapy, and watchful waiting. Alternative treatment methods
for higher-risk patients now include the development of specific
drug inhibitors of tyrosine kinase receptors. The tyrosine kinase
inhibitor imatinib mesylate (Geevec; Novartis, East Hanover,
NJ) has been successfully used in the therapy of chronic
myeloid leukemia (CML) and in a rare subtype of mesenchymal
tumors called gastrointestinal stromal tumors (GISTs). A recent
phase II trial demonstrated a high rate of response in CML at all
stages and still continues to result in durable complete re-
sponse [2,3]. In a phase II trial treating GISTs with imatinib
mesylate, a partial response was described in 50% of the
cases, compared to only a 10% response rate with the stan-
dard chemotherapy [4–6]. Imatinib mesylate inhibits the re-
ceptor tyrosine kinase (RTK) Bcr–Abl, the oncogene found in
more than 90% of patients with CMLG13 and CMLG1314, and
other Abl RTKs such as c-kit, the stem cell factor whose
oncogenetic mutation is seen in 95% of the patients with GIST,
and the platelet-derived growth factor (PDGF)-b receptor [7].
Binding of PDGF to its receptor leads to dimerization of
two subunits, a and b, either as a homodimers or heterodimers
resulting in autophosphorylation. The active receptor is able to
recruit multiple signal transduction molecules containing SH2
domains, resulting in the initiation of various signal path-
ways [8,9]. Known target pathways include the phospholipase
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C-gamma (PLC) [10], src kinase [11,12], growth factor
receptor–bound 2 (Grb2) [13], and phosphatidylinositol-3-
kinase (PI3K) pathways [14]. Therefore, there is increased
interest in using inhibitors of platelet-derived growth factor
receptor (PDGFR) in other diseases where these pathways
are implicated.
PDGFR was recently reported to be expressed in 88% of
PCa samples tested by immunohistochemistry [15] and also
in its precursor lesion, prostatic intraepithelial neoplasia
(PIN), suggesting that PDGFR expression is seen early in
PCa progression [16]. The success of treating cancer asso-
ciated with overexpression or abnormal activation of RTKs
like CML or GIST with inhibitors of RTK leads to the devel-
opment of a new therapeutic approach for the treatment of
PCa. Thus far, two phase II trials have investigated the
benefit of PDGFR inhibitors in the treatment of PCa [15,17]
and a third is currently being established with the purpose of
developing strategies to identify patients with PDGFR
expressing PCa prior to treatment [17]. In recent work, gene
expression profiles containing PDGFR-b along with four
other genes were found to be associated with a higher
prostate-specific antigen (PSA) failure rate in men treated
by radical prostatectomy for clinically localized PCa [18].
Therefore, due to the increasing interest in using the tyrosine
kinase inhibitor imatinib mesylate as an adjunct to PCa
treatment, we undertook the current study to characterize
the frequency of PDGFR-b expression in a wide range of
PCa samples, investigate associations between overexpres-
sion and other important pathologic and clinical parameters,
and identify surrogate markers of PDGFR-b expression.
Methods
Prostate Sample Collection
Prostate tissues were taken from the radical prostatecto-
my series and the rapid autopsy program at the University of
Michigan Prostate Cancer Specialized Program of Research
Excellence (SPORE) Tissue Core. Institutional Review
Board approval was obtained for the use of these samples.
Clinically localized PCa samples used for this study were
taken from a cohort of men, who underwent radical retro-
pubic prostatectomy as a monotherapy (i.e., no hormonal or
radiation therapy) for clinically localized PCa between the
years 1995 and 2001. Tumors were staged using the Tu-
mor–Node–Metastasis (TNM) system [19]. Tumors were
graded using the Gleason grading system. The median age
at time of surgery was 59 years (range 39–77 years) with
a median pretreatment PSA of 5.1 ng/ml (range 0.09–47.3
ng/ml). Gleason scores ranged from 5 to 9, with 68% having
either a Gleason score of 6 or 7. Processing of the prostatic
tissue started within 20 minutes after surgical resection. The
snap-frozen samples used for cDNA expression array anal-
ysis were all evaluated by the study pathologist. All samples
were trimmed to ensure that >95% of the sample used
represented the desired lesion. Areas of benign prostate
tissue from prostates with PCa were used as normal adja-
cent tissue in these experiments. Metastatic PCa samples
were collected from the rapid (‘‘warm’’) autopsy program as
previously described [20]. In this study, metastatic PCa from
15 rapid autopsy cases performed from 1997 to 2000 were
used. The patient’s ages ranged from 40 to 84 years, with a
median age of 65 years. All patients died with widely meta-
static PCa after extensive treatment, which included antian-
drogen and chemotherapy.
Tissue Microarray (TMA) Construction, Digital Image
Capture, and Analysis
As previously described, high-density TMAs composed of
samples from a wide range of prostate tissues were assem-
bled using an automated tissue arrayer (Beecher Instru-
ments, Silver Spring, MD) [20–23]. Three to four 0.6-mm
tissue cores were taken from each targeted lesion (i.e.,
benign PCa, or metastatic PCa) and placed into a recipient
block. Digital images were acquired from the 4 mm-thick
hematoxylin and eosin (H&E) sections as well as all immu-
nostained TMA slides using the BLISS Imaging System
(Bacus Laboratory, Lombard, IL). Protein expression was
evaluated in a blinded manner using an Internet-based TMA
presentation tool, TMA Profiler (University of Michigan, Ann
Arbor, MI). The tissue sample diagnosis was confirmed and
immunostaining was scored by the study pathologist for
protein expression intensity. All data entered into the TMA
Profiler were stored in a relational database. In order to
stratify the clinically localized PCa cases into two groups
based on their PDGFR-b protein expression, a TMA was
constructed with 60 cases, which had already been used for
expression array analysis [21,24]. Three other validation
TMAs were used, which contained benign prostatic tissue
(118 cores from 51 cases), postatrophic hyperplasia (32
cores from 29 cases), high-grade PIN (8 cores from 5 cases),
clinically localized PCa (287 cores from 109 cases), and
metastatic PCa (116 cores of metastatic PCa from 30
cases).
cDNA Expression Array Analysis
As previously reported, the spotted glass cDNA micro-
array slides used in this study included approximately 10,000
genes from the Research Genetics human cDNA clone
set [21,24]. Fluorescently labeled (Cy5) cDNA was prepared
from total RNA from each of the prostate samples. The
reference samples, a pool of benign prostate tissue, were
labeled using a second distinguishable fluorescent dye
(Cy3) using a previously established protocol (http:\\www.
microarrays.org). After labeling, the cDNA samples were
neutralized, washed, and then applied to the microarray
chips. After remaining in a hybridization water bath at 65jC
overnight, the microarray slides were processed and
scanned with a Genepix 4000 scanner (Axon Instruments,
Union City, CA). Primary analysis was done using the
Genepix software package. Images of scanned microarrays
were gridded and linked to a gene print list. Initially, data
were viewed as a scatter plot of Cy3 versus Cy5 intensities.
Cy3-to-Cy5 ratios are determined for the individual genes
along with various other quality control parameters (e.g.,
intensity over local background). The Genepix software
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analysis package flags spots as absent based on spot
characteristics. Furthermore, bad spots or areas of the array
with obvious defects were manually flagged. Spots with
small diameters (<50 mm) and spots with low signals
strengths (<350 fluorescence intensity units) over local
background in the more intense channel were discarded.
Flagged spots were not included in subsequent analyses.
Data are the ratio of the fluorescent cDNA probe signal
hybridized against the reference pool.
Immunohistochemistry
After paraffin removal and hydration, the TMA slides were
immersed in 10mM citrate buffer placed in a pressure cooker
chamber and microwaved for 10 minutes for optimal antigen
retrieval. Immunostaining was performed using a Dako
autostainer (Dako, Carpinteria, CA). Primary antibodies
[anti–PDGFR-b monoclonal (18A2), sc-19995, Santa Cruz
Biotechnology, Santa Cruz, CA; anti–PDGFR-a and anti–
PDGFR-b monoclonal, Upstate Biotechnology, Inc. Lake
Placid, NY] were incubated for 45 minutes at room temper-
ature (RT) in a 1:50 dilution and a secondary biotin-labeled
antibody for 30 minutes. Streptavidin LSA amplification
method (Dako K0679) was carried out for 30 minutes fol-
lowed by peroxidase/diaminobenzidine substrate/chroma-
gen. The slides were counterstained with hematoxylin.
Membranous (PDGFR-b) protein expression was deter-
mined by the study pathologist (M.A.R.) and immuno-
histochemistry was scored as negative (score = 1), weak
(score = 2), moderate (score = 3), or strong (score = 4), by
using a system that has been previously validated on
several TMA studies [20,21,23,25].
Stimulation of PDGFR- Phosphorylation in NIH-3T3 Cells
NIH-3T3 cells were incubated at 37jC and 5% CO2. To
enhance phosphorylation of PDGFR-b, the cell line was
stimulated with 100 ng/ml PDGF in serum-free DMEM for
10 min. Three 75-cm2 cell culture flasks were trypsinized,
and the cells were washed in phophate-buffered saline
(PBS) and fixed in 10% formalin for 1 hour. After another
step of washing with PBS, the cell pellet was gradually
dehydrated in increasing concentrations of ethanol (75–
95%) and embedded in paraffin. Phosphorylated PDGFR-b
was detected with a phospho-PDGFR-b–specific antibody
(no. 3161; Cell Signaling, Beverly, MA) at a dilution of 1:50
following the same protocol as described above.
Western Blot Analysis for Phospho-PDGFR-
To ensure that PDGFR-b was phosphorylated in the
NIH-3T3 cells, the cells were incubated in the presence of
100 ng/ml PDGF in serum-free DMEM for 10 minutes. Cell
lysis was performed with lysis buffer (1% NP-40, 50 mM
Tris HCl, pH 8, 100 mM Na-fluoride, 30 mM pyrophosphate,
2 mM Na-molybdate, 5 mM EDTA, 2 mM Na-vanadate,
10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, and
2 mM vanadate) on ice, and the cell lysates were homoge-
nized by aspiration in a syringe. Protein estimation of the
lysate was carried out using a protein quantification kit
from Bio-Rad (Hercules, CA). Twenty micrograms of lysate
(treated and untreated) was loaded on the gel and electro-
phoretically separated (12% precast sodium dodecyl sulfate
polyacrylamide gel; Invitrogen, Carlsbad, CA). The protein
was transferred on to a nitrocellulose membrane (Schleicher
and Schuell, Riviera Beach, FL) and the membrane was
stained with Ponceau red and washed for 5 minutes twice
with phosphate-buffered saline with Tween 20 (PBST).
Blocking was carried out in blocking buffer (10 ml PBST
containing 5% wt/vol nonfat dry milk) for 2 hours at RT. The
membrane was washed five times with PBST (5 minutes
each) and incubated with the primary antibody (no. 3161;
Cell Signaling) at 4jC overnight. After the membrane was
washed five times with PBST (2  5 minutes, 3  15
minutes), it was incubated with secondary antibody (anti–
goat HRP; Caltag Laboratories, Burlingham, CA) diluted
1:4000 in PBST containing 5% wt/vol BSA for 2 hours
at RT and washed five times with PBST (2  5 minutes, 3
 15 minutes). Detection was carried out using an enhanced
chemoluminescence (ECL) reagent (AmershamBiosciences,
Piscataway, NJ).
Statistical Analysis
Primary analysis of the cDNA expression data was done
using the Genepix software (Axon Instruments). Cluster
analysis (Stanford University, Palo Alto, CA) and generation
of figures with TreeView were performed using software
developed by Eisen et al. [26]. The significance analysis of
microarray (SAM) software program (Stanford University)
was used to assign a score to each gene on the basis of
change in gene expression relative to the standard deviation
of repeated measurements [27]. For genes with scores
greater than an adjustable threshold, SAM uses permuta-
tions of the repeated measurements to estimate the per-
centage of genes identified by chance, referred to as the
false discovery rate (FDR). SAM analysis was performed on
cDNA expression array data that are now in the public
domain [21]. Cluster, TreeView, and SAM software can be
obtained at http://www.dnachip.org (Stanford University).
Multiple public expression array data sets were interro-
gated usingOncomine (http://www.Oncomine.org). Additional
statistical analysis was performed using SPSS (SPSS,
Chicago, IL). At the univariate level, Kaplan-Meier analysis
was used to evaluate the cumulative risk of PSA failure
following prostatectomy. Multivariate analysis using Cox
hazards regression was used to evaluate clinical pathology
parameters and PDGFR-b expression.
Results
cDNA Microarray Analysis of PDGFR-a and PDGFR-
Examination of a range of prostate samples from benign
to metastatic PCa demonstrated different expression pat-
terns for PDGFR-a and PDGFR-b. PDGFR-a showed a
nonsignificant decrease in expression (data not shown),
whereas PDGFR-b showed no significant dysregulation with
PCa progression (Figure 1A). For example, a modest but
statistically insignificant difference was observed between
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localized PCa and metastatic PCa for PDGFR-b expression.
We performed a focused evaluation concentrating on the
localized PCa samples to determine if there is a subset
of tumors, which overexpress PDGFR-b. Approximately 5%
of clinically localized PCa demonstrated overexpression of
PDGFR-b, suggesting that this is a rare phenomenon in
clinically localized PCa (Figure 1B ). Using Oncomine
(http://www.oncomine.org), a newly developed database tool
developed by one of the coauthors (A.M.C.), we were able
to interrogate four other expression array datasets that
contained information on PDGFR-b expression on clinically
localized PCa [28–31]. After normalization of the expression
array data, as previously described [32], the results of this
analysis are presented in Figure 1C using error bars with
95% confidence intervals. None of the five studies containing
100 clinically localized PCa demonstrated a two-fold over-
expression in any sample. Table 1 presents the median
normalized expression levels.
PDGFR- Is Overexpressed in a Fraction of PCa at the
Protein Level
As the cDNA data demonstrated an upregulation solely
for the b-subunit of PDGFR and this subunit has previously
been reported to be associated with cancer progression
[33–35], we focused the analysis on the b-subunit. In order
to characterize PDGFR-b protein expression and evaluate
its potential association with PCa progression, PDGFR-b
protein expression was evaluated on a large number of
clinical samples from men with either localized or metastatic
PCa. Figure 1D demonstrates examples of weak (staining
score = 2 of 4) and strong (staining score = 4 of 4) protein
expression as determined by immunohistochemistry. Using
a system that is reproducible and tested [21,23–25,36,37],
protein staining intensity evaluated as either negative, weak,
moderate, or strong was assigned a numeric score of 1, 2,
3, or 4, respectively, for purposes of analysis. Table 2
Figure 1. PDGFR- cDNA expression and protein expression in PCa. (A) Expression array analysis was performed on a wide range of prostate samples: 10
histologically benign, 15 benign prostatic hyperplasia, 41 clinically localized PCas, and 27 metastatic prostate tumors. PDGFR- demonstrated an increase in
cDNA expression between normal and the remaining samples. The results represent trends and were not statistically significant. Expression levels were
normalized for benign samples and the error bars represent 95% confidence intervals of the fold changes in cDNA expression for PDGFR-. (B) The PDGFR-
cDNA expression distribution in 42 clinically localized PCa cases reveals only a small number of cases with increased PDGFR- expression as measured by fold
increase after normalization against benign prostate tissue samples. (C) The PDGFR- cDNA expression array results from four previously published microarray
studies. No significant differences between benign and PCa samples were seen. (D) PDGFR- protein expression as determined by immunohistochemistry in
tissue microarray samples demonstrated negative to weak expression in the majority of localized PCa samples (1 = H&E stain and 3 = weak immunostaining,
200). Strong PDGFR- protein expression was seen in approximately 1% of the localized PCa samples (2 = H&E stain, 4 = strong immunostaining, 200).
Table 1. Analysis of Normalized PDGFR-b (Unigene Hs.76144) Expression
in Benign Prostate Tissue and Localized Prostate Cancer from Five
Published Studies.
Study Name Platform Benign PCa Adjusted P Value
Dhanasekaran [21] cDNA Spotted 0.484 0.414 >1
Luo [28] Affymetrix 0.566 0.487 >1
Magee [29] Affymetrix 0.837 0.913 >1
Ramaswamy [30] Affymetrix 0.542 0.419 >1
Welsh [31] Affymetrix 0.712 0.56 0.0802
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summarizes these results. For clinically localized PCa,
approximately 5% (8 of 169) of patient samples demonstrat-
ed moderate to strong PDGFR-b expression. Metastatic PCa
showed an increased fraction with 16% positive patient
cases (5 of 30). PDGFR-b expression was not present in
benign prostate tissues examined (0 of 92), although two
benign tissue cores demonstrated a weak staining (staining
score = 2). Similar results were obtained with a second
antibody against the PDGFR-a and PDGFR-b subunits
(results not shown). In order to evaluate whether PDGFR-b
protein expression is associated with PCa progression, we
performed a univariate analysis with standard pathology and
clinical parameters. This analysis did not reveal any signif-
icant associations between PDGFR-b protein expression
and clinically relevant parameters including Gleason score
(i.e., tumor grade), tumor size, or preoperative serum PSA.
No association was identified between the development of
postsurgical PSA or biochemical failure as defined by an
elevation of PSA >0.2 ng/ml.
Detection of Phosphorylated PDGFR- in Formalin-Fixed,
Paraffin-Embedded Tissue
The expression array analysis, consistent with previous
studies on PDGFR-b expression in PCa [15,38], examined
the expression of the receptor and not specifically its acti-
vated or phosphorylated form. The initial study objective was
to evaluate the activated form of PDGFR-b in formalin-
fixed, paraffin-embedded tissues. Multiple protocols and
phospho-specific antibodies were tested before concluding
that the phosphorylation status could not be reliably deter-
mined in formalin-fixed samples. These results are summa-
rized in the following experiments. NIH-3T3 cells, a fibroblast
cell line, were stimulated with PDGF-b to increase the pres-
ence of phosphorylated PDGFR-b as has been previously
described [39]. Figure 2A shows immunoblot detection of
phospho-PDGFR-b in stimulated—but not unstimulated—
NIH-3T3 cells. Both stimulated and unstimulated NIH-3T3
cells were fixed and embedded in paraffin. PDGFR-b expres-
sion was detectable at the weak to moderate levels in both
stimulated and unstimulated cells with the anti–phospho-
PDGFR-b antibody (Figure 2B). Anti–PDGFR-b detected
the receptor in both samples at similar levels (Figure 2B).
This experiment demonstrates that antibodies against the
phosphorylated form of PDGFR-b do not appear to specifi-
cally detect phosphorylated PDGFR-b in paraffin-embedded
tissue. As we intended to characterize the fraction of pa-
tients with PCa that would be suitable for RTK inhibitor
treatment, we chose to use a nonphospho-PDGFR-b anti-
body. Therefore, taking this approach, we most probably are
overestimating the number of PCa that are suitable for
treatment targets.
DNA Microarray Characterization of
PDGFR-–Positive PCa
Hierarchical clustering of the PCa samples did not stratify
the tumors based on their PDGFR-b expression. Therefore,
a supervised approach was used. PDGFR-b overexpression,
even in a small subset of PCa, suggests that targeted
treatment would be aimed at those tumors that differ in their
expression profile. Patients with high PDGFR-b expression
might be the most suitable candidates for drug treatment.
Therefore, in order to characterize PDGFR-b overexpressing
tumors from low-expressing tumors, we used two analytic
strategies. We performed a supervised analysis using SAM
[27] by stratifying cases based either on their PDGFR-b
transcript or protein expression level with the goal of finding
other genes or pathways associated with overexpression.
In the first analysis, we divided the PCa cases into those
with high PDGFR-b transcript level as determined by cDNA
expression analysis and those with low PDGFR-b transcript
Table 2. PDGFR-b Protein Expression in Prostate Tissue and Cancer
Evaluated Using High-Density Tissue Microarray.
Prostate Tissue Cases Staining Intensity (Percentage)
Absent Weak Moderate Strong
Benign 92 90 (98%) 2 (2%) 0 0
Atrophy 27 27 (100%) 0 0 0
PIN 7 7 (100%) 0 0 0
Localized PCa 169 129 (76%) 32 (19%) 6 (4%) 2 (1%)
Metastatic PCa 30 23 (76%) 2 (7%) 1 (3%) 4 (13%)
Localized PCa, clinically localized prostate cancer.
Figure 2. Failure to detect phosphorylated PDGFR- in formalin-fixed,
paraffin-embedded tissue. NIH-3T3 cells were stimulated with 100 ng/ml
PDGF-BB for 10 minutes to increase the amount of phosphorylated
PDGFR-. (A) Immunoblot analysis demonstrates the presence of phospho-
PDGFR (190 kDa) in the stimulated cell line and the absence in the
unstimulated cell line. (B) The same antibody was used to detect phospho-
PDGFR- in paraffin blocks generated from the same cell line (same stim-
ulation). No substantial differences between both samples can be identified.
Similar lack of discrimination is seen with anti –PDGFR- antibodies between
activated and nonactivated NIH-3T3 cells (magnification, 400).
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levels. In the second analysis, we used the TMA results from
the same tumors represented on the cDNA arrays to create
two classes of localized PCa based on PDGFR-b protein
expression (i.e., absent versus present at any level).
Both methods led to similar sets of dysregulated genes.
As demonstrated in Tables 3 and 4, PDGFR-b overex-
pression was associated with a 3.8-fold increase in early
growth response 1 (Egr1). Egr1, a 59-kDa polypeptide with
several DNA-binding domains, acts as a transcriptional
activator and its expression is induced by several agents
including tissue damage, hypoxia, and growth factors includ-
ing PDGF [40]. Connective tissue growth factor (CTGF)
was also found to be upregulated 3.1-fold in the PDGFR-
b–overexpressing cases. CTGF is a downstream effector of
TGF and physiologically supports cell growth, cell develop-
ment, and cellular differentiation. As a member of a family of
immediate early genes, it is involved in cellular proliferation,
embryogenesis, and wound healing, and also in inducing
the synthesis of extracellular matrix. Activating transcription
factor 3 (ATF3) was upregulated three-fold. In its homodi-
meric form, ATF3 acts as a transcriptional repressor and, in
heterodimeric form (e.g., with c-Jun), as a transcriptional
activator. This gene was previously seen to be upregulated
in PCa [40]. a-Methylacyl-CoA racemase (AMACR), an
enzyme for peroxisomal b oxidation of branched chain fatty
acid molecules, known to be overexpressed in the majority of
PCa was 2.1-fold upregulated [23,25,37,41].
Downregulation of genes was not as dramatic as the
upregulation in the clinically localized tumors. The most
highly downregulated gene in PDGFR-b– expressing PCas
was Down syndrome critical region 1, an evolutionary con-
served protein that is located on chromosome 21 and found
to be overexpressed in Down syndrome. This gene was
2.9-fold underexpressed in PDGFR-b–expressing PCa.
A heat map showing a gene expression profile of the five
PCa cases from our dataset that expressed PDGFR-b at the
lowest level and the seven cases that expressed PDGFR-b
at the highest level, respectively, is presented in Figure 3.
This map summarizes the dysregulated genes identified
through the supervised analysis from the TMA data. PCa
cases stratified as PDGFR-b–overexpressing all had a
staining intensity from weak to strong, whereas the PCa
cases stratified as PDGFR-b–underexpressing showed an
absent staining. As the heatmap resulted from this super-
vised analysis of the expression of PDGFR-b at the protein
level, the differences in the gene expression levels among
all cases were subtle.
Discussion
The main goal of the current study was to characterize the
expression of PDGFR in a broad range of prostate tissues
and thus to determine the potential spectrum for the use of
the tyrosine kinase inhibitor imatinib mesylate. As previous
work suggested that the b-subunit of PDGFR is responsible
for a myriad of cellular functions such as migration and
proliferation and is also responsible for the angiogenic effect
of PDGF [33–35], this study concentrated on the evaluation
of expression of the b subunit.
Recent work suggested that PDGFR, a RTK, is expressed
in a high fraction of PCa [15] and therefore may represent
another possible target of imatinib mesylate or other RTK
inhibitors such as SU101. Results from a phase II clinical
trial, using the selective transient inhibitor of PDGFR auto-
phosphorylation SU101 to target PDGFR as possible cause
for development and progression of PCa in patients with
hormone-refractory prostate carcinoma, found only modest
clinical benefits [15].
Recent data linked PDGFR-b expression to PCa progres-
sion. Ko et al. [15] reported a significantly higher level of
PDGFR expression in PCa describing PDGFR expression in
88% of primary and 80% of metastatic PCa. Chott et al. [38]
also reported similar PDGFR expression levels in clinically
Table 4. Downregulated Genes in Localized Prostate Cancer Associated
with PDGFR-b Overexpression*.
Gene Name Gene IDy Fold
Downregulation
q Value
Down syndrome critical region
gene 1– like 2
132828 2.9 0.1
Myosin, light polypeptide 2,
regulatory, cardiac, slow
300051 2.8 0.1
Neuroblastoma, suppression
of tumorigenicity 1
898305 2.8 0.1
Carbonic anhydrase III 838856 2.5 0.1
v-maf 487793 2.4 0.1
Solute carrier family 2 190732 2.3 0.1
a-2-Glycoprotein 1, zinc 1456160 2.3 0.1
Growth arrest – specific 1 365826 2.2 0.1
Stearoyl-CoA desaturase 810711 2.1 0.1
Synaptotagmin I 971399 1.9 0.4
Galectin-3 811000 1.9 0.4
Developmentally regulated
GTP binding protein 1
842980 1.8 0.2
*Overexpression of PDGFR-b was determined by immunohistochemistry
of localized prostate cancer cases with associated cDNA array data. A
supervised analysis was performed using SAM, which identified dysregulated
genes.
yUnigene designation.
Table 3. Upregulated Genes in Localized Prostate Cancer Associated with
PDGFR-b Overexpression*.
Gene Name Gene IDy Fold
Upregulation
q Value
Early growth response 1 840944 3.8 0.15
Connective tissue growth factor 898092 3.1 0.1
Activating transcription factor 3 51448 3.0 0.1
Activated leukocyte cell
adhesion molecule
26617 2.7 0.1
Ribosomal protein L15 837904 2.4 0.1
SPARC-like 1 (mast9, hevin) 823871 2.2 0.05
a-Methylacyl-CoA racemase 133130 2.1 0.1
Zinc finger protein 36, C3H type,
homolog (mouse)
23804 2.1 0.17
Lumican 813823 1.8 0.24
*Overexpression of PDGFR-b was determined by immunohistochemistry of
localized prostate cancer cases with associated cDNA array data. A
supervised analysis was performed using SAM, which identified dysregulated
genes.
yUnigene designation.
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localized and metastatic PCa. These levels of expression are
significantly higher than those reported in the current study.
There are a few explanations for these differences. Chott
et al. focused solely on the expression of the a-subunit and
analyzed a small cohort consisting of eight patients. In the
study by Ko et al., both PDGFR subunits were detected in a
cohort of 44 patients with hormone-refractory (metastatic)
PCa. In the current study, we used a broad spectrum of PCa
tissue ranging from high-grade PIN to localized PCa and
hormone-refractory metastatic PCa in a cohort of 204 PCa
patients. Therefore, an explanation for the vast differences
of PDGFR expression levels in these studies compared to
ours may reside in the use of different study populations. To
get the widest perspective of PDGFR expression in PCa, we
examined a significantly larger set of cases drawn from a
wide range of patients with clinically localized PCa and
advanced hormone-refractory PCa as compared to
the previous work. Another possible explanation is that Ko
et al. used different cutoffs for grading PDGFR expression.
They considered weak staining as positive, whereas we
considered moderate and strong staining as positive. At
least at the transcript level, the cDNA microarray data
demonstrated PDGFR-b to be expressed in only a small
subset of PCa patients—a finding that was supported by the
Figure 3. Dysregulation of genes associated with PDGFR- status in localized PCa. Supervised expression array analysis was performed using SAM. Cases were
divided into high and low PDGFR- expression based on protein expression using a high-density tissue microarray. This heat map demonstrates set of genes
consistently over (red) and under (green) expressed in PCa, which either showed the highest (left) or the lowest PDGFR- expression (right) at the protein level
(see Tables 3 and 4 for details).
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immunohistochemistry results for PDGFR-b, which demon-
strated expression in only 5% of localized PCa and 16%
metastatic PCa. Given only a moderate effect of PCa treat-
ment with imatinib mesylate reported by Ko et al., one
possible conclusion is that a nontargeted approach may
not work as well as determining the PDGFR-b expression
prior to treatment.
In the second phase of analysis, we also wanted to
concentrate on the extreme cases, which demonstrated
unquestionable protein expression. Ideally, we would have
preferred to measure the activated form of the PDGFR-b.
However, as we were not able to get these antibodies to
work specifically in a large number of prostate tissues
including positive controls, we performed a cell line exper-
iment to convincingly demonstrate that reliably detecting
activated PDGFR-b is not feasible with currently available
reagents. In a cell line experiment, we detected phospho-
PDGFR-b in Western blot analysis of cell lysates only from
PDGF-stimulated NIH-3T3 cells but were unable to dis-
criminate PDGFR-b activation in the same samples once
they were fixed in formalin and embedded in paraffin.
This limits the use of immunohistochemistry as a reliable
method to distinguish PDGFR-b activation. The antibodies
against phosphorylated PDGFR are presently not suitable
for clinical use of PDGFR detection in PCa sample. The
current study estimated that PDGFR-b in PCa is low. As
few as 5% of patients with clinically localized PCa may
benefit from RTK inhibitor treatment. We also recognize
that this figure probably overestimates the percentage of
tumors with activated PDGFR-b.
In the current study, PDGFR-b protein expression was not
associated with poor prognostic indicators including ele-
vated preoperative PSA, large tumor size, higher Gleason
score, higher tumor stage, or PSA failure following surgery.
Due to multiple clinical factors such as time of diagnosis,
PDGFR-b expression may not always be associated with a
higher risk. In recent work by Singh et al., although PDGFR-b
was included in a multigene model for higher risk of bio-
chemical failure following treatment, PDGFR-b alone was
not determined to place the patient at higher risk of devel-
oping a biochemical failure [18].
The second goal of this study was to identify other genes
that may be coexpressed in PDGFR-b–positive tumors, with
the hope of identifying surrogate markers of PDGFR-b
expression and/or alternate pathway targets. This was ac-
complished by stratifying cases not by tumor progression as
we have done previously [24], but instead by evaluating the
PDGFR-b expression at the transcript and protein levels
and then dividing cases into high and low expressors. This
approach examines extreme cases in order to identify im-
portant trends due to, or associated with, the PDGFR-b
pathway. This process is an exercise in hypothesis genera-
tion with the goal of identifying more reliable and perhaps
robust biomarkers that could serve as surrogate markers of
activated PDGFR-b expression.
The majority of genes upregulated with PDGFR-b over-
expression were involved in the induction of cell proliferation,
migration, and angiogenesis. In addition, for most genes, an
overexpression had been reported in various cancers previ-
ously. The gene that was upregulated to the highest level
concurrently with PDGFR-b was the immediate early growth
response gene Egr1, which acts as a transcriptional activa-
tor. Egr1 expression itself leads to an increase in growth
factor expression including PDGF and, as such, induces
cellular proliferation and contributes to tumor progression
in PCa by accelerating tumor growth, also via accelerated
angiogenesis [42]. Although Egr1 was shown to enhance the
expression of the growth factors PDGF and TGFb1 between
30-fold and 60-fold, we did not observe overexpression of
these downstream effectors, or of the other known effectors
such as IGF II, EGF, or FGF. PDGFR activation and Egr1
lead to many similar effects, such as cellular proliferation,
differentiation, and also angiogenesis, indicating that there
might be a closer connection of these two proteins. Over-
expression of PDGFR-b was significantly concurrent with a
greater than four-fold upregulation of Egr1, which also
suggests that the use of this protein as a surrogate marker
for PDGFR-positive PCa may be feasible.
Advances in targeted drug therapy will require identifying
cohorts of patients most likely to benefit from treatment. In
the example of imatinib mesylate, where there are minimal
drug-related side effects, overtreatment is not as great a risk-
to-benefits issue. However, other novel drugs may have
more associated serious side effects, making their use only
appropriate in cases suspected to respond. The vast majority
of CML and GISTs demonstrate an overexpression or ab-
normal function of RTKs, and, therefore, treating all patients
with imatinib mesylate is a reasonable strategy. In solid
tumors, such as PCa, only a small fraction of patients is
likely to benefit from imatinib mesylate treatment as demon-
strated in the current study. Therefore, we anticipate that
advancing molecular techniques will play an important fu-
ture role in identifying these susceptible cohorts. This ideally
needs to be done before treatment, and identifying PDGFR-b
expression on prostate needle biopsy samples or performing
wide-scale genome profiling on biopsy material may be the
best way to determine treatment decisions. As suggested
by Sauter (personal communication), TMAs may be useful
in retrospectively determining which previously treated
patients may benefit from newly developed adjuvant drugs.
Using a TMA screening technique, as described in this
study, one could identify (even if the overall numbers were
small) patients most likely to benefit from treatment.
In summary, by cDNA microarray analysis, we were able
to show that PDGFR-b expression was upregulated in con-
siderably smaller subpopulations of localized and metastatic
PCa than has been previously reported. No associations
were identified between PDGFR-b expression and other
pathologic or clinical parameters. A number of genes are
upregulated and downregulated along with PDGFR-b
including Egr1, AMACR, and neuroblastoma suppressor of
tumorigenicity. The exact role of these genes in PDGFR-b–
overexpressing tumors remains unclear and must still be
determined but may characterize a subset of tumors
that proliferate at least in part by PDGFR pathway. Our
findings give experimental data for the limited likelihood of
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success in treating all PCa patients with drugs targeting
PDGFR. Determining the PDGFR expression prior to treat-
ment for selection of patients amenable for RTK inhibitor
treatment should result in a higher percentage of treatment
responders.
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